Immune checkpoint inhibitors in pediatric hematologic malignancies

Abstract

The use of immune checkpoint inhibitors as therapy in adult patients with malignancy has resulted in an improvement in overall survival. Research on the use of these drugs in pediatric oncology is just beginning. However, the results already obtained indicate the possibility of successful use of checkpoint inhibitors in children with Hodgkin’s lymphoma and some subtypes of non-Hodgkin’s lymphomas. This review analyzes the results of studies on the use of nivolumab and pembrolizumab for the treatment of children with lymphomas. The search for available literature sources was carried out in the databases PubMed, Scopus, eLibrary, Cyberleninka. The review also addresses the issue of possible predictors of response to immune checkpoint inhibitor therapy in children.